Morris, M. J., Gleave, M. E., Armstrong, A. J., Carducci, M. A., Saad, F., Lacuna, K. P., & Scher, H. I. (2014). A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results. In Journal of Clinical Oncology (Vol. 32, pp. 5022–5022). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.5022

Morris, Michael J., Martin Edwin Gleave, Andrew J. Armstrong, Michael Anthony Carducci, Fred Saad, Kristine Peregrino Lacuna, and Howard I. Scher. “A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results.” In Journal of Clinical Oncology, 32:5022–5022. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5022.

Morris MJ, Gleave ME, Armstrong AJ, Carducci MA, Saad F, Lacuna KP, et al. A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5022–5022.

Morris, Michael J., et al. “A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 5022–5022. Crossref, doi:10.1200/jco.2014.32.15_suppl.5022.

Morris MJ, Gleave ME, Armstrong AJ, Carducci MA, Saad F, Lacuna KP, Scher HI. A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5022–5022.